Intraperitoneal Injection of Cells: A Method of Delivering Cancer Cells into the Peritoneal Adipose Tissue of Murine Model

Executive Industry Relevance

This method enables preclinical modeling of ovarian cancer metastasis by delivering tumor cells into the peritoneal cavity of murine models, supporting target validation and mechanistic de-risking in early discovery. It provides a reproducible system to study cancer cell colonization in peritoneal adipose tissue, informing therapeutic hypothesis testing and portfolio triage. The approach aids in evaluating metastatic potential and stromal interactions relevant to therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses regarding ovarian cancer cell migration and colonization in peritoneal adipose tissue.
• Operational Value: Supports biological de-risking by modeling metastatic niche formation in a controlled in vivo system.

Screening & Assay Development

• Scientific Value: Prepares validated peritoneal disease models for downstream compound screening and target engagement studies.
• Operational Value: Ensures standardized cell delivery and reproducible tumor take rates for assay readiness.

Translational & Preclinical Research

• Scientific Value: Models disease-relevant peritoneal metastasis to align with clinical progression patterns in ovarian cancer.
• Operational Value: Facilitates continuity from discovery through preclinical validation by establishing a quantifiable metastatic burden.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation to preclinical efficacy testing, enabling hypothesis-driven modeling of metastatic colonization.

• Discovery Biology: Supports pathway clarification and functional target validation by modeling peritoneal niche interactions.
• Screening: Delivers standardized cell suspensions to generate reproducible peritoneal tumor models for compound evaluation.
• Analytics: Enables quantitative measurement of tumor burden and metastatic spread via imaging or histological endpoints.
• Translational Research: Connects to clinical relevance by replicating peritoneal dissemination patterns observed in ovarian cancer patients.
• Enterprise Reuse: Establishes a reusable peritoneal metastasis platform for multiple oncology programs requiring intraperitoneal disease modeling.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in metastasis models by replicating anatomic routes of ovarian cancer dissemination.
• Operational Value: Enhances reproducibility through standardized restraint, injection site selection, and cell preparation techniques.
• Strategic Value: Improves go/no-go decisions by reducing biological ambiguity in metastatic potential assessment.
• Portfolio Impact: Enables risk-adjusted prioritization of therapeutics targeting peritoneal colonization or stromal interactions.

Implementation Considerations

• Requires expertise in murine handling and aseptic injection techniques to ensure animal welfare and procedural consistency.
• Dependent on sterile syringe and needle infrastructure, including 25-gauge needles for reduced cell shearing.
• Necessitates cross-team standardization of injection volume (500 µL), depth (0.5 cm), and site selection (lower right quadrant) for reproducibility.
• Involves adaptation considerations when using different cell lines or fluorescent tags while maintaining injection parameters.
• Limited by murine peritoneal cavity volume and variability in chemotactic responses affecting colonization efficiency.

Biopharma FAQs